RIGEL PHARMACEUTICALS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $294.3 | $179.3 | $116.9 | $120.2 | $149.2 |
| Operating income | $125.5 | $24.2 | -$20.5 | -$55.5 | -$12.5 |
| Net income | $367.0 | $17.5 | -$25.1 | -$58.6 | -$17.9 |
| Balance Sheet | |||||
| Total debt | $52.5 | $60.0 | $60.0 | $40.0 | — |
| Cash Flow Statement | |||||
| Free cash flow | — | — | — | -$74.2 | $5.3 |
Shares outstanding 18.7M · Free float 73.6%
Annual filing data through FY ended December 31, 2025; float as of September 24, 2026.